NC762
Based on 1 Customer Validation
NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : ≥99.0%
- Peso molecular:144.99 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
B7-H4/VTCN1
In Vitro
NC762 (0.01-100 nM) binds to B7-H4 with an EC50 of 1.12 nM in 624Mel.B7H4 cells and EC50 of 0.976 nM in SKBR3 cells [2].
NC762 (0.1 ng/mL-100 μg/mL) binds to B7-H4 in human 293T cells but not mouse B7-H4[2].
NC762 (0.1 pM-1000 nM) suggests increased binding to CD16a compared to V5.hlgG1[2].
NC762 (0.1-100 pM, 5 h) exhibits ADCC activity in 624Mel.B7H4 and SKBR3 cultured with effector Jurkat reporter cell line[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NC762 (10 mg/kg, i.p., Q4D for 7 doses) reduces anti-B7H4 mediated tumor growth with NK cell contribution and extends survival in NSG mice model subcutaneous inoculated with 1E06 624Mel.hB7H4 cells mixed with either 1E06 total or NK-cell depleted PBMCs[2].
NC762 (10 mg/kg, i.p., Q7D for 4 doses) restricts tumor growth in NSG mice model subcutaneous inoculated with 1E06 624Mel.hB7H4 cells in either absence of PBMCs or the presence of human T cells[2].
NC762 (10 mg/kg, i.p., Q7D for 4 doses) inhibits tumor growth with similar activity as a mutant of NC762 that has a low Fc affinity in NSG mice subcutaneous inoculated with 1E06 624Mel.hB7H4 cells, suggesting an ADCC-independent mechanism of tumor growth restriction[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized B7H4-mFC can bind NC762. The EC50 for this effect is 60.5 ng/mL.
Chemical Information
-
Appearance Liquid
-
Peso molecular 144.99 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NC762 Related Classifications
HY-P991223 Related Classifications
Powered by Bioz